AlphAIalphai — Financial news for AI agents
newmediawire.comAUG 282 min read$CLBT

Kaplan Fox is Investigating Potential Securities Law Violations Against Cellebrite DI Ltd. (NASDAQ: CLBT)

Kaplan Fox is investigating Cellebrite (CLBT) for potential securities law violations. The company missed Q2 ARR estimates at $507.8M, cut full-year guidance by $15M, and announced a sudden CEO change. CLBT stock fell 29% on the news, closing at $10.80.

Original reporting
newmediawire.com
Published Aug 28, 2026, 8:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 2:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Kaplan Fox is Investigating Potential Securities Law Violations Against Cellebrite DI Ltd. (NASDAQ: CLBT) — source image
Source · newmediawire.com
Decision brief

The 30-second read

$CLBTBearishHigh
01

Why it matters

The earnings shortfall and leadership change led to a 29% intraday decline, indicating heightened risk perception.

02

Market read

The news provides a fresh, material catalyst for CLBT traders and may influence sentiment in the broader security‑software niche.

03

What to watch

The foreign entity permit requirement could be a regulatory hurdle that may affect future contracts more than the earnings miss.

Relevance 8/10Novelty 8/10Timing: post‑earnings day Aug 13

Background

Cellebrite is a provider of digital intelligence solutions; its Q2 results were previously expected to meet a $510‑$513 M ARR range.

Company-level read

Ticker impact

$CLBTBearishHigh confidence
Context

Cellebrite reported Q2 ARR miss, cut FY guidance and announced an abrupt CEO change, causing the stock to plunge 29% to $10.80.

Expected impact

Further downside pressure expected as investors reassess growth outlook.

Evidence & confidence

The combination of a revenue shortfall, lowered guidance, and sudden CEO turnover is a material negative catalyst for a Nasdaq‑listed growth company.

Market effects

Sector

Potential ripple in digital forensics and security software sector as peers may face heightened scrutiny on ARR guidance.

Regional

Limited to U.S. tech market; no broader regional effect.

Global

Minimal global impact beyond investors tracking niche security‑tech stocks.

Counterpoint

What could challenge this read

If the ARR miss is temporary and the new CEO can accelerate cloud adoption, the stock may be oversold.

Key entities

  • company
    Cellebrite DI Ltd.

    NASDAQ‑listed digital forensics firm.

  • law_firm
    Kaplan Fox & Kilsheimer LLP

    Plaintiffs' securities litigation firm soliciting information for a potential investigation.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min